AML

In an interview with Targeted Oncology, Ashley Yocum, PhD, discussed The Beat AML study and emphasized the significance of considering patient factors, such as age and genetic mutations, in treatment decisions.

In an interview with Targeted Oncology, Naval G. Daver, MD, discussed the first-in-human, phase 1/2 study of DSP-5336 in patients with relapsed or refractory acute myeloid leukemia.

PTX-252, a novel molecular drug, has received an FDA orphan drug designation for the treatment of patients with acute myeloid leukemia.

The novel CDK9 inhibitor previously received orphan drug designations in relapsed/refractory acute myeloid leukemia and peripheral T-cell lymphoma.

Orca-T, an allogeneic hematopoietic cell transplant biologic designed to control alloreactive immune responses, led to less graft-vs-host disease and favorable overall survival and relapse-free survival in patients with intermediate- and high-risk myelodysplastic syndrome.

Molecular minimal residual disease assessed after chemotherapy induction can identify patients with NPM1-mutated acute monocytic leukemia.

Results from the phase 1/2 SAVE trial demonstrated an improved objective response rate when revumenib was added to decitabine/cedazuridine, and venetoclax for patients with relapsed/refractory acute myeloid leukemia.

The required blast threshold of 20% has now been omitted from AML with defining genetic abnormalities with the exception of AML with BCR::ABL1 and AML with CEBPA mutation.

A phase 1 trial plans to be initiated in 2024 to investigate GTB-3650 for the treatment of patients with CD33-positive leukemia.

An investigational new drug application for TCB008 has been cleared by the FDA. A phase 1B trial will now assess the agent in patients with relapsed/refractory acute myeloid leukemia.

SLS009 represents a promising solution for patients with acute myeloid leukemia, addressing a significant unmet medical need. Top-line data on the agent are expected by the end of the year.

Bexmarilimab shows encouraging results when combined with standard of care treatments for patients with acute myeloid leukemia and myelodysplastic syndromes.

Based on the recommendation of an independent data monitoring committee and positive topline data, accrual in the KMT2A-rearranged cohorts of the AUGMENT-101 trial of revumenib will be stopped.

For Leukemia Awareness Month, Salman Fazal, MD, and Tibor Kovacsovics, MD, discussed the importance of biomarker testing and targeting in diagnosis, prognosis, and treatment of acute myeloid leukemia.

According to a presentation at SOHO 2023, overall survival was boosted among patients from the QuANTUM-First trial who went to transplant in first remission and were treated with quizartinib for their FLT3-ITD-positive acute myeloid leukemia.

Allogeneic HCT has shown promise as definitive treatment for patients with relapsed or refractory AML.

Roland Walter, MD, PhD, and Johannes Schetelig, MD, debated on the sequencing of allogeneic stem cell transplant in patients with relapsed or refractory acute myeloid leukemia.

There was no difference in outcomes observed with intensive vs non-intensive consolidation chemotherapy regimens before allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia.

Triplet therapy regimens now are on the horizon for patients with AML, thanks to ongoing research into targeted therapies.

Quizartinib added to induction and consolidation chemotherapy and continued as a single agent for up to 36 cycles improves the overall survival of adults with FLT3 ITD mutated AML.

Adaptation of improved methods of MRD detection are needed to better define this population at risk.

The phase 1/2 BEXMAB study is investigating the combination of bexmarilimab with standard of care in patients with hematologic malignancies.

In an interview, Jamie L. Koprivnikar, MD, discussed the importance of a machine learning approach to genomic testing in AML.

A pause on trials of magrolimab in acute myeloid leukemia will affect the screening and enrollment of patients.

Ziftomenib showed safety and efficacy in heavily pretreated patients with comutations and NPM1-mutated, relapsed/refractory acute myeloid leukemia.

Gilteritinib can be a promising bridge to allogeneic hematopoietic stem cell transplantation, according to data at the European Society for Blood and Marrow Transplantation 49th Annual Meeting.

The phase 3 QuANTUM-First trial showed that quizartinib plus chemotherapy with or without allogeneic hematopoietic stem cell transplant improved overall survival in patients with acute myeloid leukemia with a FLT3-ITD mutation.

In an interview with Targeted Oncology, Mitul Gandhi, MD, reviewed the latest guideline recommendations for the workup and treatment of acute myeloid leukemia.

Primary results from the phase 1 COVALENT 101 study demonstrate the potential of BMF-219 to induce responses in patients with various relapsed or refractory leukemias/lymphomas, including acute myeloid leukemia.

Data from the phase 3 QuANTUM-First trial have led the FDA to approve quizartinib with or without standard chemotherapy for the treatment. of FLT3-ITD-mutant acute myeloid leukemia .